CAR - T approaches involve reengineering T - cells to find and destroy cancer cells, but that process can
cause cytokine release syndrome (CRS), a life - threatening immune response NantKwest hopes to sidestep.
CAR - T treatments, including competing products from Novartis rivals Kite Pharma and Juno Therapeutics, come with the risk of potentially deadly side effects such as
cytokine -
release syndrome (CRS), in which a glut of T - cell - assisting
cytokines can
cause high fever, low blood pressure, and problems with lung oxygenation.